The space sector is experiencing a brutal capital reallocation as Elon Musk’s SpaceX towers over rivals with a jumbo debt offering that swelled to $25 billion on overwhelming demand. For Rocket Lab, the fallout has been visceral: shares tumbled more than 22% over the past week to close at €72.70 — a staggering 46% below the 52-week high set in May. The company’s operational triumphs, including a record-fast launch for the US Space Force, have been completely overshadowed by the gravitational pull of its much larger competitor.
SpaceX’s historic public listing earlier this year had already siphoned billions from the broader space investment pool. The subsequent bond issuance, upsized from an initial $20 billion target, intensified the drain. Rocket Lab’s stock took a 10% hit on Wednesday alone as the news broke, and the selling pressure barely relented until late in the week. The Nasdaq-100 index inclusion on June 22 — widely anticipated as a bullish catalyst — backfired spectacularly: investors “bought the rumor and sold the news,” sending the stock down nearly 11% on its first day in the benchmark index.
Amid the market turmoil, Rocket Lab’s engineering team delivered one of its most impressive feats. The “VICTUS HAZE” mission for the US Space Force went from contract award to liftoff in under 17 hours, smashing previous response-time records. The company is now churning out an Electron rocket every 11 days, and NASA recently booked three additional launches for scientific missions next year. On Friday, that endorsement provided a modest relief rally of 2.5%, but it did little to change the broader narrative.
Should investors sell immediately? Or is it worth buying Rocket Lab?
Compounding the sector headwinds, insider selling has raised red flags. Over the past 90 days, executives and directors have offloaded shares worth $38.5 million, with chief legal officer Arjun Kampani alone transferring $9.5 million into a fund. Meanwhile, a $3 billion at-the-market equity offering looms over the stock, threatening significant dilution. At 45 times trailing revenue against expected growth of 41%, the valuation remains stretched even by high-growth standards.
Not everyone is running for the exits. KeyBanc Capital Markets upgraded Rocket Lab to “Overweight” this week with a $135 price target, arguing that the sell-off has created an attractive entry point. The bank points to first-quarter revenue that hit $200 million and a record backlog of $2.2 billion — a figure that has doubled year over year. The disconnect between a strengthening order book and a collapsing share price, analysts say, reflects short-term market dynamics rather than fundamental deterioration.
The true inflection point for Rocket Lab lies in the fourth quarter of 2026, when the medium-lift Neutron rocket is scheduled for its maiden flight. Priced at roughly $50 million per mission, Neutron is designed to compete directly with SpaceX’s workhorse Falcon 9. A successful debut would dramatically expand Rocket Lab’s addressable market and could reshape the competitive landscape in low-Earth orbit launch services. Until then, every weekly close like Friday’s serves as a stark reminder that in the current environment, operational excellence alone is no shield against a dominant rival’s financial firepower.
Ad
Rocket Lab Stock: Buy or Sell?! New Rocket Lab Analysis from June 27 delivers the answer:
The latest Rocket Lab figures speak for themselves: Urgent action needed for Rocket Lab investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 27.
Rocket Lab: Buy or sell? Read more here...
